HOME >> MEDICINE >> NEWS
First trimester use of ACE inhibitors implicated in birth defects

The Food and Drug Administration is examining study data from Vanderbilt University Medical Center researchers, published this week in the New England Journal of Medicine, to determine if new warnings should be placed on common blood pressure medications indicating an increased risk of birth defects for babies whose mothers take these medications during the first trimester of pregnancy.

The study, led by William Cooper, M.D., M.P.H., associate professor of Pediatrics at the Monroe Carell Jr. Children's Hospital at Vanderbilt, found infants born to mothers who took angiotensin converting enzyme inhibitors (ACE inhibitors) during the first trimester of pregnancy had an increased risk of major birth defects, compared with infants whose mothers did not take these medications.

Out of 29,507 infants whose TennCare records were examined for the study, 209 were exposed to ACE inhibitors in the first trimester only. When those babies were compared to the rest of the population, including babies exposed to other types of antihypertensive medications, they had more than double the risk of major birth defects, especially of the heart and central nervous system.

Cooper is first author on the study, which includes co-authors from the Departments of Pediatrics, Preventive Medicine and Biostatistics.

"We knew ACE inhibitors were a possible cause of adverse fetal outcomes when exposure occurred later in pregnancy, but it has not been well studied in the first trimester," Cooper said. "We were very surprised that even after controlling for other risk factors, the TennCare records we examined showed a clear increase in a broad range of birth defects following first-trimester-only exposures."

This research is important because of an increase in the number of women of childbearing age who develop high blood pressure and are prescribed ACE inhibitors. These drugs already carry a warning that they may cause injury and even death to t
'"/>

Contact: Carole Bartoo
carole.bartoo@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
7-Jun-2006


Page: 1 2

Related medicine news :

1. First of its kind report on how children with brain tumors perform at school
2. First clinical trial of gene therapy for childhood blindness
3. First nationwide child health and air pollution study commences
4. First step in developing heart hormone-based pill to control high blood pressure
5. First greenhouse gas animations produced using Envisat SCIAMACHY data
6. First ozone and nitrogen dioxide measurements from MetOp-A
7. First-degree fetal heart block may be reversible
8. 10 outstanding scientists chosen as First Environmental Health Science Fellows
9. First-time mothers at increased risk for postpartum mental disorders
10. Transforming knowledge into economic benefits -- EPSRCs First Knowledge Transfer Challenge Awards
11. First Quantum Grant to fund stem cell repair of damage from stroke

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First trimester use ACE inhibitors implicated birth defects

(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... 2015 Vancouver personal injury lawyers at Jiwa ... affected by time limits. They stated that in many cases, ... or even nullify it. Many a time, delays in making ... rights under BC law. As a result, experts at Jiwa ... should consult a personal injury lawyer in order to know ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 For those ... in person, the Mesothelioma Applied Research Foundation ... on Tuesday, March 3, starting at 9:30 AM. , ... no registration. The broadcast can be accessed through any ... http://www.curemeso.org/symposium . , The Symposium is a unique event ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
(Date:2/27/2015)... 2015 Roughly three-quarters of pharmacists said ... an interchangeable biosimilar for its branded biologic counterpart ... name, according to a survey published in the ... of Managed Care & Specialty Pharmacy (JMCP). ... pharmacists would feel as confident if the products ...
(Date:2/27/2015)... 27, 2015 Pharmaceutical and biotech marketers are ... for the same indication. This can be a complex ... prevent one of their brands from gaining market share ... recent research by benchmarking firm, Best Practices, LLC, 75% ... rather than together as part of a franchise. Marketers ...
(Date:2/27/2015)... 27, 2015 The role of the Medical ... one thing hasn,t changed: face-to-face meetings are seen as ... Key Opinion Leaders. Yet at the same ... type of interaction, field medical teams within the pharmaceutical ... This is just one of the challenges addressed in ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2
Cached News: